Related references
Note: Only part of the references are listed.A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
William R. Schelman et al.
INVESTIGATIONAL NEW DRUGS (2014)
Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress
Ryan S. Soderquist et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Therapeutic potential of gossypol: An overview
Hoda Keshmiri-Neghab et al.
PHARMACEUTICAL BIOLOGY (2014)
Targeting of Smoothened for therapeutic gain
Martial Ruat et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists
James Kim et al.
CANCER CELL (2013)
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Dereck Amakye et al.
NATURE MEDICINE (2013)
The mechanisms of Hedgehog signalling and its roles in development and disease
James Briscoe et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2012)
Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential
Malini Guha
NATURE REVIEWS DRUG DISCOVERY (2012)
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum
J. Lian et al.
CELL DEATH AND DIFFERENTIATION (2011)
Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
James Kim et al.
CANCER CELL (2010)
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
Rebecca Suk Heist et al.
Journal of Thoracic Oncology (2010)
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer
Luigi Moretti et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Suzie J. Scales et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
Gossypol suppresses NF-κB activity and NF-κB-related gene expression in human leukemia U937 cells
Dong-Oh Moon et al.
CANCER LETTERS (2008)
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Yang Meng et al.
MOLECULAR CANCER THERAPEUTICS (2008)
In vivo evaluation of AT-101 (R-(-)-Gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration
Robert D. Loberg et al.
NEOPLASIA (2007)
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists
Matthias Lauth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Oxysterols pathway in are novel activators of the hedgehog pluripotent mesenchymal cells
Jennifer R. Dwyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins
Guoping Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2
Benjamin D. Zeitlin et al.
CANCER RESEARCH (2006)
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins
D. Zhai et al.
CELL DEATH AND DIFFERENTIATION (2006)
(-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo
Keith G. Wolter et al.
NEOPLASIA (2006)
Molecular mechanisms of Sonic hedgehog mutant effects in holoprosencephaly
T Maity et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer
JY Shao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/- p53-/- mice
JT Romer et al.
CANCER CELL (2004)
Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis
DX Hou et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2004)
Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells
MC Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
DN Watkins et al.
NATURE (2003)
Small molecule modulation of Smoothened activity
JK Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Medulloblastoma growth inhibition by Hedgehog pathway blockade
DM Berman et al.
SCIENCE (2002)
Hedgehog signaling in animal development: paradigms and principles
PW Ingham et al.
GENES & DEVELOPMENT (2001)
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial
C Van Poznak et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine
J Taipale et al.
NATURE (2000)
Share Paper
